Edition:
United States

Aptose Biosciences Inc (APTO.OQ)

APTO.OQ on NASDAQ Stock Exchange Capital Market

3.41USD
20 Apr 2018
Change (% chg)

$-0.19 (-5.28%)
Prev Close
$3.60
Open
$3.62
Day's High
$3.62
Day's Low
$3.39
Volume
79,875
Avg. Vol
81,926
52-wk High
$3.96
52-wk Low
$0.78

Chart for

About

Aptose Biosciences Inc. (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates... (more)

Overall

Beta: 2.39
Market Cap(Mil.): $100.15
Shares Outstanding(Mil.): 29.30
Dividend: --
Yield (%): --

Financials

  APTO.OQ Industry Sector
P/E (TTM): -- 188.22 33.60
EPS (TTM): -0.52 -- --
ROI: -133.04 -0.74 13.19
ROE: -133.04 -2.80 15.00

BRIEF-Aptose Biosciences Establishes New At-The-Market Facility

* APTOSE BIOSCIENCES INC SAYS ENTERED INTO AN "AT-THE-MARKET" SALES AGREEMENT WITH CANTOR FITZGERALD & CO

Mar 28 2018

BRIEF-Aptose Reports Qtrly Loss Of $0.12‍​ Per Share

* APTOSE REPORTS RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2017

Mar 27 2018

BRIEF-Aptose Biosciences Announces License Agreement for Dual BET/Kinase Targeting Program With OHM Oncology ‍​

* APTOSE BIOSCIENCES - ‍ AGREEMENT PROVIDES OHM ONCOLOGY RIGHTS FOR DEVELOPMENT, MANUFACTURE AND COMMERCIALIZATION OF APL-581

Mar 07 2018

BRIEF-Aptose Biosciences Inc Files For Stock Shelf Of Upto $100 Mln

* APTOSE BIOSCIENCES INC FILES FOR STOCK SHELF OF UPTO $100 MILLION - SEC FILING Source text : http://bit.ly/2BJGvqH Further company coverage:

Feb 07 2018

BRIEF-FDA Grants Orphan Drug Designation To Aptose Biosciences For CG’806 In Acute Myeloid Leukemia

* FDA GRANTS ORPHAN DRUG DESIGNATION TO APTOSE BIOSCIENCES FOR CG’806 IN ACUTE MYELOID LEUKEMIA Source text for Eikon: Further company coverage:

Dec 26 2017

BRIEF-Aptose Biosciences Inc Q3 loss per share C$0.14

* Aptose reports results for the third quarter ended September 30, 2017

Nov 14 2017

BRIEF-Aptose enters into $15.5 mln common shares purchase agreement with Aspire Capital Fund, Llc

* Aptose enters into $15.5 million common shares purchase agreement with Aspire Capital Fund, Llc

Oct 30 2017

Earnings vs. Estimates